Alnylam Pharmace. buy Truist Financial Co.
Start price
17.10.25
/
50%
€418.20
Target price
17.10.26
€457.16
Performance (%)
-31.78%
Price
20.02.26
€285.30
Summary
This prediction is currently active. Massive losses of -31.78% have been the result for the BUY prediction by Truist_Financial_Co_. This prediction currently runs until 17.10.26. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 7.946% | 7.946% |
| iShares Core DAX® | 1,43 % | 2,63 % |
| iShares Nasdaq 100 | 1,89 % | -0,46 % |
| iShares Nikkei 225® | -1,62 % | 11,10 % |
| iShares S&P 500 | 1,92 % | 1,16 % |
Comments by Truist_Financial_Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Truist Financial Corporation from $459.00 to $535.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Truist_Financial_Co_ for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€343.00
08.01.26
08.01.26
€454.00
08.01.27
08.01.27
-16.82%
20.02.26
20.02.26
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€275.00
21.07.25
21.07.25
€331.29
21.07.26
21.07.26
3.75%
20.02.26
20.02.26